NCT04167657 (STAR) is a Phase 2 clinical trial of Sintilimab in Carcinoma, Non-Small Cell Lung, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04167657?

NCT04167657 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04167657?

Interventions in NCT04167657: Sintilimab.

What condition does NCT04167657 study?

NCT04167657 studies Carcinoma, Non-Small Cell Lung.

Is NCT04167657 still recruiting?

NCT04167657 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT04167657: STAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SinTilimab After Radiation (STAR Study)

Completed Phase 2 Last updated 19 September 2024

What this trial tests

Phase 2 trial testing Sintilimab in Carcinoma, Non-Small Cell Lung in 14 participants. Completed in 30 April 2024.

Timeline

15 April 2019

Primary endpoint
30 November 2023

30 April 2024

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	15 April 2019
Primary completion	30 November 2023
Estimated completion	30 April 2024
Sites	1 location across China

Drugs / interventions tested

Sintilimab — full drug profile →

Conditions studied

Carcinoma, Non-Small Cell Lung — all drugs for Carcinoma, Non-Small Cell Lung →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Carcinoma, Non-Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm multi-center phase II clinical study, which aims to investigate the efficacy and safety of sintilimab after radiotherapy in patients with advanced NSCLC who failed first-line or second-line systemic treatment.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Radiotherapy combined with immunotherapy: the dawn of cancer treatment.
Zhang Z, Liu X, Chen D, Yu J. · · 2022 · cited 463× · PMID 35906199 · DOI 10.1038/s41392-022-01102-y
Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.
Kong Y, Ma Y, Zhao X, Pan J, et al · · 2021 · cited 34× · PMID 33859942 · DOI 10.3389/fonc.2021.638873
Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients.
Frąk M, Krawczyk P, Kalinka E, Milanowski J. · · 2021 · cited 9× · PMID 33799560 · DOI 10.3390/cancers13061222
Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single-Arm Study.
Feng X, Liu X, Guan H, Chen C, et al · · 2025 · cited 1× · PMID 40116232 · DOI 10.1111/1759-7714.70043
The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study.
Chen L, Xu W, Qi WX, Xu F. · · 2023 · cited 1× · PMID 37033350 · DOI 10.21037/tcr-22-1151
Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review).
Li Q, Cai YQ, Shao LH, Qi YX, et al · · 2025 · PMID 40799300 · DOI 10.3892/ol.2025.15215

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for Carcinoma, Non-Small Cell Lung

Currently open trials in the same condition.

NCT07227298 — Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer · Phase 1, PHASE2 · recruiting
NCT06868277 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic · Phase 3 · recruiting
NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
NCT04389632 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors · Phase 1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04167657 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04167657.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing